Daniel D. Burton - Jun 3, 2021 Form 4 Insider Report for Health Catalyst, Inc. (HCAT)

Role
Chief Executive Officer, Director
Signature
/s/ Daniel Orenstein, as Attorney-in-Fact
Stock symbol
HCAT
Transactions as of
Jun 3, 2021
Transactions value $
-$7,120,803
Form type
4
Date filed
6/7/2021, 08:23 PM
Previous filing
Jun 3, 2021
Next filing
Jun 9, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HCAT Common Stock Options Exercise $852K +78.9K +27.85% $10.80 362K Jun 3, 2021 Direct
transaction HCAT Common Stock Sale -$4.01M -76K -20.98% $52.79 286K Jun 3, 2021 Direct F1, F2
transaction HCAT Common Stock Sale -$154K -2.9K -1.01% $53.22 283K Jun 3, 2021 Direct F1, F3
transaction HCAT Common Stock Options Exercise $792K +73.3K +25.89% $10.80 357K Jun 4, 2021 Direct
transaction HCAT Common Stock Options Exercise $304K +19.2K +5.38% $15.84 376K Jun 4, 2021 Direct
transaction HCAT Common Stock Sale -$4.9M -92.5K -24.62% $53.01 283K Jun 4, 2021 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HCAT Stock Option (Right to Buy) Options Exercise $0 -78.9K -19.39% $0.00 328K Jun 3, 2021 Common Stock 78.9K $10.80 Direct F5
transaction HCAT Stock Option (Right to Buy) Options Exercise $0 -19.2K -10.41% $0.00 165K Jun 4, 2021 Common Stock 19.2K $15.84 Direct F6
transaction HCAT Stock Option (Right to Buy) Options Exercise $0 -73.3K -22.36% $0.00 255K Jun 4, 2021 Common Stock 73.3K $10.80 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 4, 2021, in accordance with Rule 10b5-1.
F2 Represents the weighted average sale price of the shares sold ranging from $52.08 to $53.06 per share, inclusive.
F3 Represents the weighted average sale price of the shares sold ranging from $53.08 to $53.57 per share, inclusive.
F4 Represents the weighted average sale price of the shares sold ranging from $52.54 to $53.25 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (2) though (4).
F5 25% of the 747,223 shares underlying the option vested in an annual installment on September 25, 2019 and the remaining balance vested or will vest in equal monthly installments until the option vests in full on September 25, 2022.
F6 25% of the 299,748 shares underlying the option vested in an annual installment on February 5, 2020 and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023.